Rather than delve into the minutia of daily happenings, look at...

Rather than delve into the minutia of daily happenings, look at the bigger picture to help in trying to predict the future.

We know:-

1 It will be at least 5 years before there is sufficient self generating income to pay for an ongoing research program for all the possibilities that OmniCAR has capabilities.

2 A guess is that it could take $1 billion in trials to prove/gain approval for the 3 OmniCAR targets plus PTX 100 and maybe PTX 200 in those intervening 5 years.

3 Income from CellPryme will be minimal but helpful. PTX 100 Income could not be expected for 3 years and PTX 200 longer if pursued.

Therefore, a large increase in funds will be required soon after the start of the first OmniCAR trials.
The methods of obtaining this level of capital are broad as many are trying to guess as well as the number of times it may be needed. I have no opinion but consider a US dual listing should be one way and that all methods need to be non-dilutive.

With current market conditions this would be a big ask at present but maybe not be in the next Calendar year when the ‘me too’ competition has exited stage left - the US has decided to have a debt crisis or not – the state of current wars – or any number of sociopolitical/economic black swan events. So timing may be delayed by external factors other than data – but should happen eventually because of the advantages documented.

It will be imperative that some good data is available from OmniCAR trials before any major capital raise for its development. Similarly good news from PTX 100 trial extension would allow a raise for its development/approval trial so that it too can become self funding for further development.

We are all obviously in a flat spot waiting for developments beyond our control – something long term holders can handle but leaves traders flummoxed. SYC is advising of his difficulties with changing FDA requirements affecting timing – not capabilities, so we will remain in a waiting phase until it all resolves itself with time.

I recall being antsy with PTX in such a flat spot a few years ago, then OmniCAR popped, CellPryme recently and the collaborations with TF and MDA firmly de-risked the company and put it on a path for investment potential rather than speculation. It now needs good data, capital and time to complete the transition and we will know it is well underway when the large investors arrive, presumably with a capital raise after the competition has abated and when we are one of the few left standing.

With the main capital raise behind us and great data as expected then it will be game on for growth as the company matures and only then IMO that we could expect a major player to try a takeover. IMO TF will collaborate and not try and control the research function. They are smart enough to see the future and their position in being part of the cell supply chain for their share of this new paradigm in oncology and other possibilities.

So it’s back to waiting for the announcements of the known developments and the data quality to lead to timing of expected pivot points.